BioSpace News Archive

XPhyto Therapeutics Corp. is pleased to announce it has commenced a pilot project with its rapid COVID-19 PCR test in a point-of-care setting in Germany.

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that early clinical data from a Phase 1 dose-escalation study of Tessa’s TT11X allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy in patients with CD30-positive lymphoma will be featured in a podium presentation

With pharmaceutical and biotechnology medical affairs teams now seen as key strategic partners in ensuring the introduction of new treatments into clinical practice, Medscape has launched Medscape Medical Affairs, a new business unit that will support those teams in serving as a strategic pillar alongside Clinical Development and Commercialization teams, to accelerate the adoption of life-changing therapies into clinical practice.

photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku, Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) the leader in the pharmaceutical development, translation and global commercialization of 5-aminolevulinic acid

Global health services company Cigna Corporation reported strong first quarter 2021 results driven by focused execution across its businesses.

LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular damage and diseases, today announced research investigators lead by Drs. Hakan Kaymak, Inken Becker and Hartmut Schwahn, from the Macula Retina Centre of Breyer Kaymak & Klabe Eye Clinic in Dusseldorf, Germany

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) announced its results today for the first quarter ended March 31, 2021.

Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in May: Bank of America 2021 Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. E.T. UBS Global Healthcare Virtual Conference on Monday, May 24, 2021 at 10:00 a.m. E.T.

-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 -- -- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 -- -- Cortrophin ® Gel sNDA re-filing on track for Q2 2021 submission -- -- Strengthened R&D engine and enhanced generics and CDMO business through pending acquisition of Novitium Pharma--

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of HUTCHMED, will participate in a virtual fireside chat at the Bank of America 2021 Health Care Conference on Tuesday, May 11, 2021 at 8:00 a.m. Eastern Daylight Time (EDT).